


Substrate for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known			
				Application Number	10/634,477		
				Filing Date	August 4, 2003		
				First Name Inventor	Lehmann, et al.		
Sheet	1	of	3	Attorney Docket Number	21368 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A1	5,733,761		Treco et al.	03/31/1998		
	A2	5,641,670		Treco et al.	06/24/1997		
	A3	5,733,746		Treco et al.	03/31/1998		
	A4	5,994,127		Selden et al.	11/30/1999		
	A5	6,528,313		Le Mouellic et al.	03/04/2003		
	A6	5,981,214		Skoultschi	11/09/1999		
	A7	5,272,071		Chappel	12/21/1993		
	A8	5,359,030		Ekwuribe	10/25/1994		
	A9	5,681,811		Ekwuribe	10/28/1997		
	A10	4,179,337		Davis et al.	12/18/1979		
	A11	5,324,650		Obzansky et al.	06/28/1994		
	A12	6,583,272		Bailon	06/24/2003		
	A13	5,672,662		Harris et al.	09/30/1997		
	A14	5,541,158		Vance et al.	07/30/1996		
	A15	4,745,099		Akamatsu et al.	05/17/1988		
	A16	6,333,306		Lehmann et al.	12/25/2001		
	A17	US 2002/0160956 A1		Lehmann et al.	10/2002		
	A18	5,376,632		Konings et al.	12/27/1994		
	A19	6,372,715		Kaltwasser et al.	04/16/2002		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	EP 640619			Amgen Inc.	03/01/1995	
	B2	WO 01/02017			F.Hoffmann-La Roche AG	01/11/2001	
	B3	EP 1064951			F.Hoffmann-La Roche AG	01/03/2001	
	B4	EP 539167			Ortho Pharmaceutical Corp.	04/28/1993	
	B5	EP 605963			Ortho Pharmaceutical Corp.	07/13/1994	
	B6	WO 93/25212			Amgen Inc.	12/23/1993	
	B7	WO 94/20069			Amgen Inc.	09/15/1994	
	B8	WO 95/11924			Enzon, Inc.	05/04/1995	
	B9	EP 584876			Sterling Winthrop Inc.	03/02/1994	
	B10	WO 92/16555			Enzon, Inc.	10/01/1992	
	B11	WO 94/28024			Enzon, Inc.	12/08/1994	
	B12	WO 97/04796			Protein Delivery Inc.	02/13/1997	
	B13	WO 98/32466			Polymasc Pharmaceutical PLC	07/30/1998	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.




Substituted for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Complete if Known			
		Application Number	10/634,477		
		Filing Date	August 4, 2003		
		First Name Inventor	Lehmann, et al.		
Sheet	2	of	3	Attorney Docket Number	21368 US

FOREIGN PATENT DOCUMENTS

B14	DE 3924705	Boehringer Mannheim GmbH	01/31/1991
B15	WO 01/87329	F.Hoffmann-La Roche AG	11/22/2001
B16	EP 0411678	Genetics Institute Inc.	02/06/1991
B17	EP 0205564	Genetics Institute Inc.	12/30/1986
B18	EP 0286439	Ortho Pharmaceutical Copr.	10/12/1988
B19	WO 97/09996	Boehringer Mannheim GmbH	03/20/1997
B20	WO 98/41226	Boehringer Mannheim GmbH	09/24/1998

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	P. Lehmann, M. Volkmann, J. Lotz, A. Baldauf, R. Roeddiger, poster presented at the AACC/CSCC, Annual Meeting, July 29 - August 2, 2001, Chicago Illinois	
	C2	Abstract corresponding to DE 3924705	
	C3	Grützmaier P., et al., <i>Clinical Nephrology</i> , vol. 38, pp 92-97, 1992	
	C4	Wick, M.; Pinggera, W.; Lehmann, P., <i>Eisenstoffwechsel Diagnostik und Therapie der Anämien</i> , 3 rd edition, Springer, Wien, NY, pp 5-14, 38-55, 65-80, 94-98, Sept. 1996	
	C5	Sunder-Plassmann G., et al., <i>Journal of the American Society of Nephrology</i> , 5, (3), pp 478 (1994).	
	C6	Gasche C., et al., <i>Dig. Dis. Sci.</i> , 39, (9) pp 1930-4 (1994).	
	C7	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 10, (11), pp 2070-2076 (1995).	
	C8	Mercuriali F. et al., <i>Erythropoiesis: New Dimensions in the Treatment of Anaemia</i> , 6/3, pp 67-76, (1995).	
	C9	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (9), pp 1797-1802, (1996).	
	C10	Taylor J. E., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (6), pp 1079-1083, (1996).	
	C11	Breyman, et al., <i>Eur. J. Clin. Invest.</i> , pp 123-30.	
	C12	Goodnough, et al., <i>Haematology</i> , 1(2), pp 163-166.	
	C13	MacDougall (1994) Monitoring of Iron Status & Iron Supplementation in Patients Treated with Erythropoietin. <i>Current Opinion in Nephrology & Hypertension</i> 3(6) pgs. 620-625	
	C14	Taylor et al. (1996) Regular low-dose Intravenous Iron Therapy Improves Response to Erythropoietin in Haemodialysis Patients. <i>Nephrology, Dialysis, & Transplantation</i> 11(6) pgs. 1079-1083	
	C15	Means, Jr. (1995) Erythropoietin in the Treatment of Anemia in Chronic Infectious, Inflammatory, & Malignant Diseases. <i>Current Opinion in Hematology</i> 2(3) pgs. 210-213	



Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/634,477		
		Filing Date	August 4, 2003		
		First Name Inventor	Lehmann, et al.		
Sheet	3	of	3	Attorney Docket Number	21368 US

NON PATENT LITERATURE DOCUMENTS

<input checked="" type="checkbox"/>	C16	Adamson (1996) Erythropoietin, Iron Metabolism, & Red Blood Cell Production. <i>Seminars In Hematology</i> 33(2) pgs. 5-9		
<input type="checkbox"/>	C17	Mercuriali & Inghilleri (1995) Iron Administration to Optimise the Effect of r-HuEPO in the Surgical Setting. <i>Erythropoiesis: New Dimensions in the Treatment of Anemia</i> 6(3) pgs. 67-76		
<input checked="" type="checkbox"/>	C18	Pincus et al. (August, 1990) Multicultural Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis. <i>The American Journal of Medicine</i> 89(2) pgs. 161-168.		
Examiner Signature	Hope Robinson		DATE CONSIDERED	8/30/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

135388

[illegible]

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Use several sheets if necessary)

Sheet	22	of	2
-------	----	----	---

Application Number	10/634,477
Filing Date	August 4, 2003
First Name Inventor	Lehmann
Group Art Unit	1636
Examiner Name	H. R.
Attorney Docket Number	21368

U.S. PATENT DOCUMENTS


[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ³	Kind Code ³ (if known)			
CH	B21	WO 03/25583	A2	F.Hoffmann-La Roche AG	03-27-2003		
Examiner Signature	Chae Robinson	Date Considered			8/30/05		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MREP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Final word mark communication to applicant.
²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 *Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.
 137290